NewcelX Return on Equity

NewcelX (NCEL) currently reports a ROE of -11.92%. That is above the Healthcare sector average of -75.84%. Use the charts on this page to explore NewcelX's ROE history and peer comparisons.

NewcelX's ROE of -11.92% is higher than the Healthcare sector average of -75.84%. That is roughly 84.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but NewcelX's current -11.92% should be judged against Healthcare norms (sector average: -75.84%) and against NCEL's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -11.92%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.84%. From there, open related valuation or income-statement pages for NewcelX, and consider following NCEL for alerts when major investors trade the stock.

NewcelX is classified in the Healthcare sector. On ROE, it currently shows -11.92% versus a sector average near -75.84%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NCEL with unrelated industries.